Principal Investigator
|
Benjamin Ebert, MD, PhD, is the George P. Canellos, MD, and Jean S. Canellos Professor of Medicine at Harvard Medical School, President and CEO of Dana-Farber Cancer Institute, a former Howard Hughes Medical Institute Investigator, and an Institute Member of the Broad Institute. The Ebert laboratory focuses on the molecular basis and treatment of hematologic malignancies and its non-malignant precursor conditions, with a particular focus on myelodysplastic syndromes (MDS) and clonal hematopoiesis. The Ebert laboratory demonstrated that lenalidomide, a derivative of thalidomide, binds the CRL4CRBN E3 ubiquitin ligase and induces degradation of specific substrates. Subsequent research has examined novel mechanisms of drug-induced protein degradation that expand the spectrum of protein substrates that can be targeted pharmacologically. Dr. Ebert is an elected member of the National Academy of Medicine, the American Academy of Arts and Sciences, the American Society for Clinical Investigation, and the Association of American Physicians. He served as President of the American Society for Clinical Investigation in 2017. He received the William Dameshek Prize from the American Society of Hematology, the Meyenburg Prize for Cancer Research, the Sjöberg Prize from the Royal Swedish Academy of Sciences, and the Korsmeyer Award from the American Society for Clinical Investigation. He has received awards from Harvard Medical School and the London Society for mentorship. Dr. Ebert received a bachelor's degree from Williams College and a doctorate from Oxford University as a Rhodes Scholar in the laboratory of Sir Peter Ratcliffe. He completed an M.D. from Harvard Medical School, a residency in internal medicine at Massachusetts General Hospital, and a fellowship in hematology/oncology at the Dana-Farber Cancer Institute. |